Immunotarget retrospective analysis evaluated response to ICI therapy in metastatic NSCLC patients with oncogenic driver alterations including Kirsten Rat Sarcoma virus (KRAS), EGFR, v-raf murine sarcoma viral oncogene homolog B1 (BRAF), human epidermal growth factor receptor 2 (HER2), mesenchymal epithelial transition factor (MET), mutations, and ALK, c-ros oncogene 1 (ROS1) and rearranged during transfection (RET) rearrangements. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.